Literature DB >> 11336934

Complications and prognostic factors in Vogt-Koyanagi-Harada disease.

R W Read1, A Rechodouni, N Butani, R Johnston, L D LaBree, R E Smith, N A Rao.   

Abstract

PURPOSE: To identify associations between complications of disease and final visual acuity in patients with Vogt-Koyanagi-Harada disease and to identify prognostic factors for disease outcome.
METHODS: All patients diagnosed with Vogt-Koyanagi-Harada disease at the Doheny Eye Institute or the Los Angeles County/University of Southern California Medical Center between 1983 and 1997 were reviewed. Data extracted included initial and final visual acuities, age, gender, ethnicity, complications, treatment, duration of disease, and number of recurrences.
RESULTS: One hundred one patients with Vogt-Koyanagi-Harada disease were identified, 68 (67%) of which were female. Mean age was 34 +/- 14 years (range, 8 to 75 years). Asians presented at a significantly older age than all other groups. One hundred three eyes (51%) developed at least one complication, including cataract in 84 eyes (42%), glaucoma in 54 eyes (27%), choroidal neovascular membranes in 22 eyes (11%), and subretinal fibrosis in 13 eyes (6%). Patients who developed at least one complication had a significantly longer median duration of disease and number of recurrent episodes of inflammation (P =.0001 for each) than did those patients who developed no complications. Statistically significant associations existed between poor final visual acuity and greater numbers of complications (P =.001), greater age at onset (P =.03), a longer median duration of disease (P =.03), and greater number of recurrent episodes of inflammation (P =.0004). Eyes possessing a better visual acuity at presentation were more likely to have a better visual acuity at final follow-up (P =.001).
CONCLUSIONS: Factors associated with a worse final acuity included increasing numbers of complications, greater age at onset, and worse acuity at presentation.

Entities:  

Mesh:

Year:  2001        PMID: 11336934     DOI: 10.1016/s0002-9394(01)00937-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  49 in total

1.  Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Authors:  H Nida Sen; Lea T Drye; Debra A Goldstein; Theresa A Larson; Pauline T Merrill; Peter R Pavan; John D Sheppard; Alyce Burke; Sunil K Srivastava; Douglas A Jabs
Journal:  Ocul Immunol Inflamm       Date:  2012-04       Impact factor: 3.070

2.  Headache, red eyes, blurred vision and hearing loss. Diagnosis: Vogt-Koyanagi-Harada syndrome.

Authors:  Errol Wei'en Chan; Srinivasan Sanjay; Benjamin Chong Ming Chang
Journal:  CMAJ       Date:  2010-05-17       Impact factor: 8.262

3.  The spectrum of Vogt-Koyanagi-Harada disease in Iran.

Authors:  Alireza Hedayatfar; Seyedeh Maryam Hosseini; Nasser Karimi; Khalil Ghasemi Falavarjani; Negin Badie; Mahsa Zameni; Masoud Soheilian
Journal:  Int Ophthalmol       Date:  2017-03-04       Impact factor: 2.031

4.  Spectrum and visual outcomes of Vogt-Koyanagi-Harada disease in Argentina.

Authors:  Verónica E Giordano; Ariel Schlaen; Martín J Guzmán-Sánchez; Cristobal Couto
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

Review 5.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

6.  Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease.

Authors:  S R Nowilaty; M Bouhaimed
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

7.  Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings.

Authors:  Daniel V Vasconcelos-Santos; Elliott H Sohn; Srinivas Sadda; Narsing A Rao
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

8.  Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome.

Authors:  Lihteh Wu; Teodoro Evans; Mario Saravia; Ariel Schlaen; Cristobal Couto
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

9.  Management of ocular complications of Vogt-Koyanagi-Harada syndrome.

Authors:  Irfan Perente; Canan Asli Utine; Hanefi Cakir; Vedat Kaya; Ilknur Tugal Tutkun; Omer Faruk Yilmaz
Journal:  Int Ophthalmol       Date:  2007-10-19       Impact factor: 2.031

10.  Inflammatory choroidal neovascularization.

Authors:  Piergiorgi Neri; Marta Lettieri; Cinzia Fortuna; Mara Manoni; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.